Lisa Young, MD
Endocrinology, Diabetes & Metabolism · Ocala, FLNPI 1861694911
Payments from drug & device makers
Across 497 payments — averaging $17.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Sanofi-aventis U.S. LLC$2K
- Lilly USA, LLC$905
- Amgen$523
- Mannkind Corporation$479
- Boehringer Ingelheim$463
- plus $3K from 30 others
What the payments were for
- Food & beverage$8,66399%
- Education$621%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 122 | $1,645 |
| Sanofi-aventis U.S. LLC | 78 | $1,610 |
| Lilly USA, LLC | 56 | $905 |
| Amgen | 22 | $523 |
| Mannkind Corporation | 26 | $479 |
| Boehringer Ingelheim | 27 | $463 |
| Tandem Diabetes Care, Inc. | 17 | $358 |
| Medtronic(2 entities) | 16 | $347 |
| AstraZeneca(2 entities) | 22 | $337 |
| Xeris Pharmaceuticals, Inc. | 15 | $278 |
| Insulet Corporation | 10 | $171 |
| AbbVie | 9 | $170 |
| Novartis | 9 | $167 |
| IBSA Pharma Inc. | 8 | $149 |
| Abbott | 7 | $124 |
| GSK | 1 | $120 |
| Merck | 7 | $119 |
| Amarin Pharma, Inc. | 7 | $112 |
| Dexcom, Inc. | 6 | $111 |
| Corcept Therapeutics | 5 | $94 |
| Chiesi USA, Inc. | 4 | $90 |
| BETA Bionics, Inc. | 4 | $80 |
| Bayer | 3 | $56 |
| Madrigal Pharmaceuticals | 2 | $46 |
| Clarus Therapeutics Inc. | 2 | $38 |
| Radius Health, Inc. | 2 | $29 |
| Sequel Med Tech, LLC | 1 | $22 |
| GRT US Holding, Inc. | 1 | $22 |
| Acerus Pharmaceuticals Corporation | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Acella Pharmaceuticals, LLC | 1 | $17 |
| Cequr Corporation | 1 | $14 |
| Ascendis Pharma Endocrinology Inc | 1 | $14 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
| Kvk-tech, Inc. | 1 | $13 |
| Lifescan, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,784 in reported general payments places this provider in the 60th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 540 | $753,336 |
| MounjaroTirzepatide | 435 | $599,675 |
| FarxigaDapagliflozin Propanediol | 265 | $367,248 |
| JardianceEmpagliflozin | 197 | $265,509 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 134 | $219,595 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 184 | $215,795 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 128 | $202,575 |
| TrulicityDulaglutide | 98 | $166,911 |
| RybelsusSemaglutide | 85 | $144,642 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 47 | $124,443 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 108 | $95,813 |
| Tresiba Flextouch U-100Insulin Degludec | 139 | $95,448 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 68 | $70,775 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 168 | $67,640 |
| Tresiba Flextouch U-200Insulin Degludec | 42 | $66,699 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog, Novolog Mix 70-30 | $1,645 | $960,134759 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $905 | $805,110628 claims |
| AstraZenecaFarxiga | $337 | $367,248265 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Glyxambi | $463 | $343,062258 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $1,610 | $215,795184 claims |
| MerckJanuvia | $119 | $27,92232 claims |
| AbbVieSynthroid | $170 | $15,060186 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Ocala
- Richard PratleyOrlando$9.2M
- Jose MandryOcoee$9.1M
- Steven SmithOrlando$7.9M
- Barry HorowitzWest Palm Beach$7.1M
- Tina ThethiOrlando$3.8M
- David SuttonJacksonville$3.1M
- Lorena Lewy-AlterbaumHollywood$3.1M
- Mae Sheikh AliJacksonville$2.9M
- James MageeJacksonville$2.7M
- Rodolfo GalindoMiami$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.